Media Kit

Featured News

Announcement

Parkinson's Disease

BlueRock Therapeutics announces publication in Nature of 18-month data from Phase 1 clinical trial for bemdaneprocel, an investigational cell therapy for Parkinson’s disease

Bayer and BlueRock Therapeutics logos side by side on a light blue background

Announcement

Ophthalmology

BlueRock Therapeutics receives FDA Fast Track Designation for OpCT-001 for the treatment of primary photoreceptor diseases

Bayer and BlueRock Therapeutics logos side by side on a light blue background

Announcement

Clinical Trials

Parkinson's Disease

BlueRock Therapeutics advances investigational cell therapy bemdaneprocel for treating Parkinson’s disease to registrational Phase III clinical trial

multicolor title graphic for cell & gene the podcast featuring BlueRock Therapeutics

Podcast

Cell & Gene The Podcast | Inside BlueRock Therapeutics' Parkinson's Disease Trial

See All

Media Library

Lab
Headshots
Logos
Offices

Two BlueRockers in Safety Gear Focused

BlueRocker Focused in Lab 2

BlueRocker using Microscope

Close Up BlueRocker in Lab

BlueRocker Using Equipment in Lab

Containers in NYC Lab

BlueRocker in Safety Goggles in Lab

BlueRocker Smiling in Lab 2

BlueRocker sitting in lab

BlueRocker in Lab and Safety Gear

BlueRocker on Computer in Lab

Equipment 4

Two BlueRockers Looking at Computer

Equipment 3

Equipment 2

Science 2

Two BlueRockers Focused in Lab

Close Up of Sample in Lab

BlueRocker Focused in Lab 2

BlueRockers Speaking in Lab

BlueRocker Team in lab

BlueRocker Smiling in Lab

Scientist in a lab working through a microscope

Scientist placing a platform card onto a microscope

Employee looking at a computer screen image of a cell

Scientist working under a hood

Scientists in lab

Alan Stevenson

General Counsel

Amit Rakhit

Chief Development and Medical Officer

Seth Ettenberg, Ph.D.

President and Chief Executive Officer

Natasha Rathee

SVP, Finance

Rebecca Milbury

SVP, People and Culture

Melissa Mudrick

SVP, Quality and Compliance

Craig Beasley

Chief Technology Officer

Stefan Irion, M.D.

Chief Scientific Officer

BlueRock Logo White

BlueRock Therapeutics Logo Full Color

BlueRock Therapeutics Dark Blue Logo

Black BlueRock Therapeutics Logo

Cambridge

New York

Berlin

Toronto

BlueRock Logo on Building

BRTx Logo in Office 2

Media Contact

Contact@BlueRockTX.com

Video

B-Roll

B-Roll: Lab 1

B-Roll: Lab 2

B-Roll: Lab 3

B-Roll: Lab 4

B-Roll: Lab 5

B-Roll: Lab 6

B-Roll: PSC-Derived Cardiomyocytes

Explore more with BlueRock

Cell Therapy

Our Programs

Our Pipeline

Careers

Keep up to date with the latest BlueRock Therapeutics news and updates

Follow BlueRock Therapeutics on Linkedin